# DANHEART (H-HeFT and Met-HeFT)

Study · id `cardio:ct-nct03514108` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03514108](<https://clinicaltrials.gov/study/NCT03514108>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03514108

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1100 participants.

## Technical summary

Registry record NCT03514108. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2025-12-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1100 participants (enrolled count; ClinicalTrials.gov record NCT03514108, source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)
- Started: 2018-03-01 (actual) (ClinicalTrials.gov record NCT03514108, source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT03514108, source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)
- Completion: 2025-12-31 (actual) (ClinicalTrials.gov record NCT03514108, source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT03514108, source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03514108-2026-06-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: DANHEART (H-HeFT and Met-HeFT)
- Acronym: DANHEART
- Condition: Heart Failure
- Condition: Diabetes
- Intervention (Drug): Hydralazine Isosorbide Dinitrate
- Intervention (Drug): Placebo Oral Tablet
- Intervention (Drug): Metformin Hydrochloride
- Intervention (Drug): Placebo Oral Tablet
- Lead sponsor: Henrik Wiggers
- Lead sponsor class: OTHER
- Collaborator: Danish Heart Foundation
- Collaborator class: OTHER
- Collaborator: Danish Council for Independent Research
- Collaborator class: OTHER
- Collaborator: The Danish Regions: Foundation for Medical Research
- Collaborator class: UNKNOWN
- Collaborator: Novo Nordisk Foundation
- Collaborator class: OTHER
- Collaborator: The Aase og Ejnar Danielsen Foundation
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as a collaborator: Danish Heart Foundation (`cardio:org-danish-heart-foundation`)

## Provenance

Content hash: 1113958da1e3af6b9ee67ec344e9b4fa905694e38e9efca67d2a67b70afdec59
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
